does using daratumumab make response-monitoring difficult?
Published 7 years ago • 42K plays • Length 3:24Download video MP4
Download video MP3
Similar videos
-
1:00:47
using daratumumab to treat high-risk myeloma patients
-
11:11
rationale for selinexor treatment in daratumumab-refractory multiple myeloma patients
-
5:00
subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma
-
36:40
what a newly diagnosed patient needs to know
-
8:16
daratumumab, carfilzomib, lenalidomide and dex for hr smoldering multiple myeloma: ascent trial
-
6:59
teclistamab in combination with sub-q daratumumab and lenalidomide in myeloma pts: majestec-2
-
3:52
is dara being used in the frontline setting for myeloma patients?
-
2:50:58
imf patient & family webinar - back to basics: from testing to tailored therapy
-
3:17
what new tests are on the horizon for myeloma monitoring?
-
1:27
cytof flow cytometry in determining daratumumab response in myeloma
-
2:49
what does the approval of darzalex faspro™ mean for myeloma patients?
-
2:56:05
advances in myeloma treatments: what patients & caregivers need to know
-
10:26
understanding darzalex faspro
-
4:16
what is the latest from the international myeloma foundation’s black swan research initiative?
-
4:22
mass spectrometry and response monitoring in multiple myeloma
-
59:40
ongoing myeloma care
-
48:06
the latest insights on immune therapies in myeloma | 2023 imf patient and family seminar
-
1:03:05
the international myeloma foundation's imwg conference series: making sense of treatment 2021
-
57:52
first-line or frontline therapy options in multiple myeloma | 2023 imf patient and family seminar